Shares of Cytek BioSciences Inc. (CTKB) recently surpassed the average analyst 12-month target price of $5.56, trading at $5.71 per share. This movement prompts analysts to reconsider their valuations or adjust their target prices based on the company’s current performance.
There are four distinct analyst targets, with one predicting a low of $4.75 and another anticipating a high of $7.50, resulting in a standard deviation of $1.297. Currently, Cytek holds three strong buy ratings and two hold ratings, with an average rating of 1.8, indicating favorable analyst sentiment.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
